In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment right up until disease progression or the participants are unable to tolerate the study drugs. Celastrol was identified to be a Myb inhibitor that suppressed C/EBPβ action https://abbv-744-in-acute-myeloid13467.blogdemls.com/31820192/a-simple-key-for-abbv-744-for-targeted-cancer-therapy-treatment-unveiled